Literature DB >> 28514814

[Possibilities and Limitations of OCT-Angiography in Patients with Central Serous Chorioretinopathy].

B Cakir1, M Reich1, S J Lang1, A Bühler1, A Stahl1, D Böhringer1, H Agostini1, C Lange1.   

Abstract

Purpose Central serous chorioretinopathy (CSC) is a commonly acquired maculopathy characterized by the accumulation of subretinal fluid at the posterior pole. This study aims to analyze optical coherence tomography angiography (OCTA) findings in patients with acute and chronic CSC and to compare them to conventional imaging methods. Methods A series of 43 consecutive eyes of 29 patients diagnosed with CSC and 18 eyes of 9 healthy control subjects were included in this retrospective study. The OCTA images were assessed and compared to conventional fluorescence (FAG) and indocyanine green angiography (ICG). Results All CSC patients demonstrated abnormal areas of focal hypo- and hyperperfusion in the choriocapillaris. These were particularly evident in patients with chronic atrophic CSC. FAG and ICG imaging revealed leakage points in 10 of 43 eyes and choroidal neovascularization (CNV) in 3 of 43 eyes. OCTA imaging confirmed leakage points in 4 out of 10 cases and choroidal neovascularization in 2 out of 3 cases. In one case, OCTA demonstrated a CNV which was not detectable by FAG/ICG. Conclusion OCTA reveals areas of focal hypo- and hyperperfusion in the choriocapillaris in patients with CSC. Due to the inability to detect plasma flow, OCTA is not suitable to detect leakage points in CSC with confidence. However, OCTA reliably detects CNV in CSC even in the absence of exudative activity and may, therefore, represent an important supplement in the diagnosis of CSC. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2017        PMID: 28514814     DOI: 10.1055/s-0043-102576

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  7 in total

1.  Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.

Authors:  Vladimir Sheptulin; Konstantine Purtskhvanidze; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-10       Impact factor: 3.117

Review 2.  Micropulse Laser Treatment of Retinal Diseases.

Authors:  Maciej Gawęcki
Journal:  J Clin Med       Date:  2019-02-13       Impact factor: 4.241

3.  Optical Coherence Tomography Angiography Compared with Indocyanine Green Angiography in Central Serous Chorioretinopathy.

Authors:  Jie Hu; Jinfeng Qu; Zhenyu Piao; Yuou Yao; Guosheng Sun; Mengyang Li; Mingwei Zhao
Journal:  Sci Rep       Date:  2019-04-16       Impact factor: 4.379

4.  Optical coherence tomography angiography versus fluorescein angiography in diagnosing choroidal neovascularization in chronic central serous chorioretinopathy.

Authors:  Reema Bansal; Mohit Dogra; Samyak Mulkutkar; Deeksha Katoch; Ramandeep Singh; Vishali Gupta; Mangat Ram Dogra; Amod Gupta
Journal:  Indian J Ophthalmol       Date:  2019-07       Impact factor: 1.848

5.  Swept-source optical coherence tomography angiography alleviates shadowing artifacts caused by subretinal fluid.

Authors:  Michael Reich; Daniel Boehringer; Kai Rothaus; Bertan Cakir; Felicitas Bucher; Moritz Daniel; Stefan J Lang; Wolf A Lagrèze; Hansjuergen Agostini; Clemens Lange
Journal:  Int Ophthalmol       Date:  2020-04-24       Impact factor: 2.031

6.  Longitudinal Analysis of the Choriocapillaris Using Optical Coherence Tomography Angiography Reveals Subretinal Fluid as a Substantial Confounder in Patients with Acute Central Serous Chorioretinopathy.

Authors:  Michael Reich; Daniel Böhringer; Bertan Cakir; Felicitas Bucher; Moritz Daniel; Stefan Lang; Wolf Lagrèze; Hansjürgen Agostini; Clemens Lange
Journal:  Ophthalmol Ther       Date:  2019-10-25

Review 7.  Applications of Multimodal Imaging in Central Serous Chorioretinopathy Evaluation.

Authors:  Mary Ho; Gabriel Li; Andrew Mak; Danny Ng; Lawrence Iu; Frank Lai
Journal:  J Ophthalmol       Date:  2021-07-24       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.